Frontlight ResearchEarly access
SuspendedPhase 2
IORT on Borderline Resectable Pancreatic Cancer
Key facts
- Who runs it
- Universita di Verona
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Suspended
- Phase
- Phase 2
- People taking part
- 100 people, planned
- Started
- 1 Oct 2019
- Expected to end
- 30 Dec 2027
- Type of study
- Interventional
- Treatments tested
- Intraoperative radiotherapy
- Record updated
- 7 May 2024
- Why it stopped
- Logistic and financial reasons
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- • Biopsy-proven, previously untreated borderline resectable PC, defined according to the NCCN guidelines v1.2019; Age 18-80 years; Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1; Adequate bone marrow function (absolute neutrophil count ≥1500 per cubic millimeter; platelet count ≥100.000 per cubic millimeter; hemoglobin level ≥10 g per deciliter), liver function (serum total bilirubin level ≤1.5 times the upper limit of the normal range), and renal function (creatinine clearance ≥50 ml per minute); Ability to understand the characteristics of the clinical trial; Written informed consent
Who cannot take part
- • Ampullary, biliary, or duodenal adenocarcinoma; pancreatic adenocarcinoma in the background of an intraductal papillary mucinous neoplasia (IPMN), other uncommon pancreatic adenocarcinomas (acinar-cell, squamous, giant-cell osteoclastic-like); Invasive cancer in the last 5 years requiring radiation therapy to the upper abdomen or chemotherapy; Symptomatic heart failure or coronary artery disease; Pregnant or lactating women; Impaired mental state or language problems
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This phase II study investigates the efficacy of IORT for patients with borderline resectable pancreatic cancer. The purpose of the study is to investigate whether the addition of IORT, after FOLOFIRINOX-base chemotherapy, and SBRT, increases the 3-year survival rate. A total of 101 patients will be enrolled, and these patients will receive IORT of 10 to 20 Gy, according to the resection status (to the tumor bed after resection, or to the tumor in situ in case of non-resection).
The group in the trial
- IORT groupTreatment being tested
Intraoperative administration of 10 to 20 Gy after surgery or as an "in situ" treatment in case resection will not be performed
Treatment: Intraoperative radiotherapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase II Study of Primary Chemotherapy, Stereotactic Body Radiation Therapy, and Intraoperative Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
- Publications
- Record updated
- 7 May 2024